<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39469425</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1482-1826</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Journal of pharmacy &amp; pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</Title><ISOAbbreviation>J Pharm Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles.</ArticleTitle><Pagination><StartPage>13635</StartPage><MedlinePgn>13635</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13635</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/jpps.2024.13635</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has raised concern regarding respiratory system diseases and oral inhalation stands out as an attractive non-invasive route of administration for pulmonary diseases such as chronic bronchitis, cystic fibrosis, COVID-19 and community-acquired pneumonia. In this context, we encapsulated azithromycin in polycaprolactone nanoparticles functionalized with phospholipids rich in dipalmitoylphosphatidylcholine and further produced a fine powder formulation by spray drying with monohydrated lactose. Nanoparticles obtained by the emulsion/solvent diffusion-evaporation technique exhibited a mean hydrodynamic diameter around 195-228 nm with a narrow monomodal size distribution (PdI &lt; 0.2). Nanoparticle dispersions were spray-dried at different inlet temperatures, atomizing air-flow, aspirator air flow, and feed rate, using lactose as a drying aid, resulting in a maximal process yield of 63% and an encapsulation efficiency of 83%. Excipients and the dry powder formulations were characterized in terms of morphology, chemical structure, thermal analyses and particle size by SEM, FTIR, DSC/TGA and laser light diffraction. The results indicated spherical particles with 90% at 4.06 µm or below, an adequate size for pulmonary delivery. Aerosolization performance in a NGI confirmed good aerodynamic properties. Microbiological assays showed that the formulation preserves AZM antimicrobial effect against <i>Staphylococcus aureus</i> and <i>Streptococcus</i> pneumoniae strains, with halos above 18 mm. In addition, no formulation-related cytotoxicity was observed against the human cell lines BEAS-2B (lung epithelial), HUVEC (endothelial) and HFF1 (fibroblasts). Overall, the approach described here allows the production of AZM-PCL nanoparticles incorporated into inhalable microparticles, enabling more efficient pulmonary therapy of lung infections.</AbstractText><CopyrightInformation>Copyright © 2024 Madrid Sani, Ramos-Rocha, Sarcinelli, Chaves, Rocha, Léo, Cerize, Zanin, Feitosa and Rangel-Yagui.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madrid Sani</LastName><ForeName>Alison Tatiana</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Bionanomanufacturing Center, Technological Research Institute, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemical and Pharmaceutical Technology, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Rocha</LastName><ForeName>Khellida Loiane V</ForeName><Initials>KLV</Initials><AffiliationInfo><Affiliation>Bionanomanufacturing Center, Technological Research Institute, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemical and Pharmaceutical Technology, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarcinelli</LastName><ForeName>Michelle Alvares</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Laboratory of Micro and Nanotechnology, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaves</LastName><ForeName>Marcelo Henrique da Cunha</ForeName><Initials>MHDC</Initials><AffiliationInfo><Affiliation>Laboratory of Micro and Nanotechnology, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Helvécio Vinícius Antunes</ForeName><Initials>HVA</Initials><AffiliationInfo><Affiliation>Laboratory of Micro and Nanotechnology, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Léo</LastName><ForeName>Patrícia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Bionanomanufacturing Center, Technological Research Institute, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerize</LastName><ForeName>Natália Neto Pereira</ForeName><Initials>NNP</Initials><AffiliationInfo><Affiliation>Bionanomanufacturing Center, Technological Research Institute, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanin</LastName><ForeName>Maria Helena Ambrosio</ForeName><Initials>MHA</Initials><AffiliationInfo><Affiliation>Bionanomanufacturing Center, Technological Research Institute, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feitosa</LastName><ForeName>Valker Araujo</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Department of Biochemical and Pharmaceutical Technology, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rangel-Yagui</LastName><ForeName>Carlota de Oliveira</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>Department of Biochemical and Pharmaceutical Technology, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pharm Pharm Sci</MedlineTA><NlmUniqueID>9807281</NlmUniqueID><ISSNLinking>1482-1826</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011208">Powders</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011091">Polyesters</NameOfSubstance></Chemical><Chemical><RegistryNumber>24980-41-4</RegistryNumber><NameOfSubstance UI="C016240">polycaprolactone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005079">Excipients</NameOfSubstance></Chemical><Chemical><RegistryNumber>J2B2A4N98G</RegistryNumber><NameOfSubstance UI="D007785">Lactose</NameOfSubstance></Chemical><Chemical><RegistryNumber>2644-64-6</RegistryNumber><NameOfSubstance UI="D015060">1,2-Dipalmitoylphosphatidylcholine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="Y">Azithromycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011208" MajorTopicYN="Y">Powders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010316" MajorTopicYN="Y">Particle Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011091" MajorTopicYN="Y">Polyesters</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058995" MajorTopicYN="N">Dry Powder Inhalers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005079" MajorTopicYN="N">Excipients</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007785" MajorTopicYN="N">Lactose</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013211" MajorTopicYN="N">Staphylococcus aureus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085642" MajorTopicYN="N">Spray Drying</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015060" MajorTopicYN="N">1,2-Dipalmitoylphosphatidylcholine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013296" MajorTopicYN="N">Streptococcus pneumoniae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">azithromycin</Keyword><Keyword MajorTopicYN="N">dry powder inhaler</Keyword><Keyword MajorTopicYN="N">polycaprolactone</Keyword><Keyword MajorTopicYN="N">pulmonary diseases</Keyword><Keyword MajorTopicYN="N">spray-drying</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39469425</ArticleId><ArticleId IdType="pmc">PMC11513329</ArticleId><ArticleId IdType="doi">10.3389/jpps.2024.13635</ArticleId><ArticleId IdType="pii">13635</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu M, Jia X, Liu H, He R, Zhang X, Shao Y, et al. Role of TRPV1 in respiratory disease and association with traditional Chinese medicine: a literature review. Biomed &amp; Pharmacother (2022) 155:113676. 10.1016/j.biopha.2022.113676</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113676</ArticleId><ArticleId IdType="pubmed">36088856</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MD, Fee C, Mace SE, Maughan B, Perkins JC, Jr, Kaji A, et al. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med (2021) 77:e1–57. 10.1016/j.annemergmed.2020.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2020.10.024</ArticleId><ArticleId IdType="pubmed">33349374</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y, Tomooka K, Naito T, Tanigawa T. Decreased number of inpatients with community-acquired pneumonia during the COVID-19 pandemic: a large multicenter study in Japan. J Infect Chemother (2022) 28:709–13. 10.1016/j.jiac.2022.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2022.01.013</ArticleId><ArticleId IdType="pmc">PMC8776425</ArticleId><ArticleId IdType="pubmed">35115238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinks TSC, Cureton L, Knight R, Wang A, Cane JL, Barber VS, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med (2021) 9:1130–40. 10.1016/S2213-2600(21)00263-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00263-0</ArticleId><ArticleId IdType="pmc">PMC8270523</ArticleId><ArticleId IdType="pubmed">34252378</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Chang S, Du G, Li Y, Gong J, Wei Z, et al. Encapsulation of azithromycin into polymeric microspheres by reduced pressure-solvent evaporation method. Int J Pharmaceutics (2012) 433:79–88. 10.1016/j.ijpharm.2012.04.081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2012.04.081</ArticleId><ArticleId IdType="pubmed">22583850</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng J, Cao D, Zheng D, Qian ZM, Huang C, Shen H, et al. Cold spells linked with respiratory disease hospitalization, length of hospital stay, and hospital expenses: exploring cumulative and harvesting effects. Sci Total Environ (2023) 863:160726. 10.1016/j.scitotenv.2022.160726</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2022.160726</ArticleId><ArticleId IdType="pubmed">36502973</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother (1992) 26:1253–61. 10.1177/106002809202601014</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/106002809202601014</ArticleId><ArticleId IdType="pubmed">1330097</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Gu J, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol (2015) 13:369–76.e3. 10.1016/j.cgh.2014.07.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2014.07.054</ArticleId><ArticleId IdType="pmc">PMC4321982</ArticleId><ArticleId IdType="pubmed">25111234</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Prinsen JK, Bersell KR, Shen W, Yermalitskaya L, Luis PB, et al. Azithromycin causes a novel proarrhythmic syndrome. Circ Arrhythmia Electrophysiol (2017) 10:e003560–12. 10.1161/CIRCEP.115.003560</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCEP.115.003560</ArticleId><ArticleId IdType="pmc">PMC5396181</ArticleId><ArticleId IdType="pubmed">28408648</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Jazairi AS, Alotaibi HS. Possible azithromycin-induced life-threatening arrhythmia requiring extracorporeal membrane oxygenation support: a case report. Am J Case Rep (2020) 21:e926951–5. 10.12659/AJCR.926951</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AJCR.926951</ArticleId><ArticleId IdType="pmc">PMC7669954</ArticleId><ArticleId IdType="pubmed">33180749</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathaneni V, Kulkarni NS, Shukla SK, Farrales PT, Kunda NK, Gupta V, et al. Systematic development and optimization of inhalable pirfenidone liposomes for non-small cell lung cancer treatment. Pharmaceutics (2020) 12:206. 10.3390/pharmaceutics12030206</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12030206</ArticleId><ArticleId IdType="pmc">PMC7150896</ArticleId><ArticleId IdType="pubmed">32121070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechanteur A, Evrard B. Influence of composition and spray-drying process parameters on carrier-free DPI properties and behaviors in the lung: a review. Pharmaceutics (2020) 12:55. 10.3390/pharmaceutics12010055</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12010055</ArticleId><ArticleId IdType="pmc">PMC7022846</ArticleId><ArticleId IdType="pubmed">31936628</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaurasiya B, Zhao YY. Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics (2020) 13:31–28. 10.3390/pharmaceutics13010031</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13010031</ArticleId><ArticleId IdType="pmc">PMC7824629</ArticleId><ArticleId IdType="pubmed">33379136</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrus R, Benke E, Farkas Á, Balásházy I, Szabó-Révész P. Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties. Eur J Pharm Sci (2018) 123:20–7. 10.1016/j.ejps.2018.07.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2018.07.030</ArticleId><ArticleId IdType="pubmed">30016647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibum I, Hagedoorn P, Frijlink HW, Grasmeijer F. Characterization and formulation of isoniazid for high-dose dry powder inhalation. Pharmaceutics (2019) 11:233. 10.3390/pharmaceutics11050233</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11050233</ArticleId><ArticleId IdType="pmc">PMC6572553</ArticleId><ArticleId IdType="pubmed">31086107</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultana N, Arayne MS, Hussain F, Fatima A. Degradation studies of azithromycin and its spectrophotometric determination in pharmaceutical dosage forms. Pak J Pharm Sci (2006) 19:98–103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16751118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamzehloo M, Karimi J, Eghbali N, Mirzakhani M, Aghapoor K, Darabi HR, et al. A new blend of polymeric encapsulation of azithromycin by spray-drying with a pH responsive in drug release. Drying Technol (2017) 35:1688–95. 10.1080/07373937.2016.1269807</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07373937.2016.1269807</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z, Milton-mcgurk L, Tang P, Chan H, Farina D, Cheng S, et al. An experimental study of the effect of individual upper airway anatomical features on the deposition of dry powder inhaler formulations. J Aerosol Sci (2024) 177:106320. 10.1016/j.jaerosci.2023.106320</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaerosci.2023.106320</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunological Methods (1983) 65:55–63. 10.1016/0022-1759(83)90303-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-1759(83)90303-4</ArticleId><ArticleId IdType="pubmed">6606682</ArticleId></ArticleIdList></Reference><Reference><Citation>Suárez N, Texeira E. Optimal conditions for Streptococcus pneumoniae culture: in solid and liquid media. Methods Mol Biol (2019) 1968:3–10. 10.1007/978-1-4939-9199-0_1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9199-0_1</ArticleId><ArticleId IdType="pubmed">30929201</ArticleId></ArticleIdList></Reference><Reference><Citation>e Silva SS, Carvalho JWP, Aires CP, Nitschke M. Disruption of Staphylococcus aureus biofilms using rhamnolipid biosurfactants. J Dairy Sci (2017) 100:7864–73. 10.3168/jds.2017-13012</Citation><ArticleIdList><ArticleId IdType="doi">10.3168/jds.2017-13012</ArticleId><ArticleId IdType="pubmed">28822551</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomoni R, Léo P, Montemor AF, Rinaldi BG, Rodrigues MFA. Antibacterial effect of silver nanoparticles in Pseudomonas aeruginosa . Nanotechnology, Sci Appl (2017) 10:115–21. 10.2147/NSA.S133415</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NSA.S133415</ArticleId><ArticleId IdType="pmc">PMC5499936</ArticleId><ArticleId IdType="pubmed">28721025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro MO, Gomes Md S, Senna SG, Rossetti MLR, Fonseca Ld S. Avaliação de testes rápidos em microplacas usando indicadores de viabilidade celular para determinação da susceptibilidade de cepas de Mycobacterium tuberculosis à isoniazida e rifampicina. J Bras Pneumol (2004) 30:365–70. 10.1590/s1806-37132004000400011</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1806-37132004000400011</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilho AL, Caleffi-Ferracioli KR, Canezin PH, Dias Siqueira VL, de Lima Scodro RB, Cardoso RF, et al. Detection of drug susceptibility in rapidly growing mycobacteria by resazurin broth microdilution assay. J Microbiol Methods (2015) 111:119–21. 10.1016/j.mimet.2015.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mimet.2015.02.007</ArticleId><ArticleId IdType="pubmed">25683207</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz CD, Shah S, Tammela P. Defining conditions for biofilm inhibition and eradication assays for Gram-positive clinical reference strains. BMC Microbiol (2018) 18:173–9. 10.1186/s12866-018-1321-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-018-1321-6</ArticleId><ArticleId IdType="pmc">PMC6215609</ArticleId><ArticleId IdType="pubmed">30390625</ArticleId></ArticleIdList></Reference><Reference><Citation>Buhecha MD, Lansley AB, Somavarapu S, Pannala AS. Development and characterization of PLA nanoparticles for pulmonary drug delivery: co-encapsulation of theophylline and budesonide, a hydrophilic and lipophilic drug. J Drug Deliv Sci Technol (2019) 53:101128. 10.1016/j.jddst.2019.101128</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2019.101128</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Develop Ind Pharm (1998) 24:1113–28. 10.3109/03639049809108571</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03639049809108571</ArticleId><ArticleId IdType="pubmed">9876569</ArticleId></ArticleIdList></Reference><Reference><Citation>Galindo-Rodriguez S, Allémann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res (2004) 21:1428–39. 10.1023/B:PHAM.0000036917.75634.be</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:PHAM.0000036917.75634.be</ArticleId><ArticleId IdType="pubmed">15359578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira IJ, de Menezes LR, Tavares MIB. Obtaining PCL/tea tree oil particles with antimicrobial capacity and high cytocompatibility. Polym Bull (2024). 10.1007/s00289-024-05455-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00289-024-05455-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Qiu H, Yin S, Wang H, Li Y. Polymeric drug delivery system based on pluronics for cancer treatment. Molecules (2021) 26:3610–23. 10.3390/molecules26123610</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26123610</ArticleId><ArticleId IdType="pmc">PMC8231161</ArticleId><ArticleId IdType="pubmed">34204668</ArticleId></ArticleIdList></Reference><Reference><Citation>Nwazojie CC, Obayemi JD, Salifu AA, Borbor-Sawyer SM, Uzonwanne VO, Akpan UM, et al. Targeted drug-loaded PLGA-PCL microspheres for specific and localized treatment of triple negative breast cancer. J Mater Sci Mater Med (2023) 34:41. 10.1007/s10856-023-06738-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10856-023-06738-y</ArticleId><ArticleId IdType="pmc">PMC10397127</ArticleId><ArticleId IdType="pubmed">37530973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangal S, Nie H, Xu R, Guo R, Cavallaro A, Zhou Q, et al. Physico-chemical properties, aerosolization and dissolution of co-spray dried azithromycin particles with L-leucine for inhalation. Pharm Res (2018) 35:28. 10.1007/s11095-017-2334-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-017-2334-9</ArticleId><ArticleId IdType="pmc">PMC5918295</ArticleId><ArticleId IdType="pubmed">29374368</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggag YA, Faheem AM. Evaluation of nano spray drying as a method for drying and formulation of therapeutic peptides and proteins. Front Pharmacol (2015) 6:140–5. 10.3389/fphar.2015.00140</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2015.00140</ArticleId><ArticleId IdType="pmc">PMC4493383</ArticleId><ArticleId IdType="pubmed">26217227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotabarren IM, Bertín D, Razuc M, Ramírez-Rigo MV, Piña J. Modelling of the spray drying process for particle design. Chem Eng Res Des (2018) 132:1091–104. 10.1016/j.cherd.2018.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cherd.2018.01.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamady Hussein MA, Guler E, Rayaman E, Cam ME, Sahin A, Sezgin Mansuroglu D, et al. Dual-drug delivery of Ag-chitosan nanoparticles and phenytoin via core-shell PVA/PCL electrospun nanofibers. Carbohydr Polym (2021) 270:118373. 10.1016/j.carbpol.2021.118373</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2021.118373</ArticleId><ArticleId IdType="pubmed">34364617</ArticleId></ArticleIdList></Reference><Reference><Citation>Karolewicz B, Górniak A, Owczarek A, Zurawska-Płaksej E, Piwowar A, Pluta J, et al. Thermal, spectroscopic, and dissolution studies of ketoconazole-pluronic F127 system. J Therm Anal Calorim (2014) 115:2487–93. 10.1007/s10973-014-3661-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10973-014-3661-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Eedara BB, Rangnekar B, Doyle C, Cavallaro A, Das SC. The influence of surface active L-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders. Int J Pharmaceutics (2018) 542:72–81. 10.1016/j.ijpharm.2018.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.03.005</ArticleId><ArticleId IdType="pubmed">29524618</ArticleId></ArticleIdList></Reference><Reference><Citation>Listiohadi Y, Hourigan JA, Sleigh RW, Steele RJ. Thermal analysis of amorphous lactose and α-lactose monohydrate. Dairy Sci Technol (2009) 89:43–67. 10.1051/dst:2008027</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/dst:2008027</ArticleId></ArticleIdList></Reference><Reference><Citation>Maswadeh H. Incompatibility of paracetamol with pediatric suspensions containing amoxicillin, azithromycin and cefuroxime axetil. Pharmacol Pharm (2017) 08:355–68. 10.4236/pp.2017.811026</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/pp.2017.811026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sánchez-Aguinagalde O, Meaurio E, Lejardi A, Sarasua JR. Amorphous solid dispersions in poly(ϵ-caprolactone)/xanthohumol bioactive blends: physicochemical and mechanical characterization. J Mater Chem B (2021) 9:4219–29. 10.1039/d0tb02964e</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d0tb02964e</ArticleId><ArticleId IdType="pubmed">33998613</ArticleId></ArticleIdList></Reference><Reference><Citation>Agalloco JP, Augsburger LL, Bergstrom DH, Borman P, Schoneker DR, Srinivasan A, et al. Pharmaceutical technology. 7th ed. NJ, USA: Pharmatech; (2017).</Citation></Reference><Reference><Citation>Garnier S, Petit S, Mallet F, Petit MN, Lemarchand D, Coste S, et al. Influence of ageing, grinding and preheating on the thermal behaviour of α-lactose monohydrate. Int J Pharmaceutics (2008) 361:131–40. 10.1016/j.ijpharm.2008.05.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2008.05.023</ArticleId><ArticleId IdType="pubmed">18617338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramírez-Agudelo R, Scheuermann K, Gala-García A, Monteiro APF, Pinzón-García AD, Sinisterra RD, et al. Hybrid nanofibers based on poly-caprolactone/gelatin/hydroxyapatite nanoparticles-loaded Doxycycline: effective anti-tumoral and antibacterial activity. Mater Sci Eng C (2018) 83:25–34. 10.1016/j.msec.2017.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msec.2017.08.012</ArticleId><ArticleId IdType="pubmed">29208285</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimohammadi M, Fakhraei O, Moradi A, Kabiri M, Moradi A, Tamayol A, et al. Controlled release of azithromycin from polycaprolactone/chitosan nanofibrous membranes. J Drug Deliv Sci Technol (2022) 71:103246. 10.1016/j.jddst.2022.103246</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2022.103246</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kayal T, Panetta D, Canciani B, Losi P, Tripodi M, Burchielli S, et al. Evaluation of the effect of a gamma irradiated DBM-pluronic F127 composite on bone regeneration in wistar rat. PLoS One (2015) 10:e0125110. 10.1371/journal.pone.0125110</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0125110</ArticleId><ArticleId IdType="pmc">PMC4405568</ArticleId><ArticleId IdType="pubmed">25897753</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid MA, Elgied AA, Alhamhoom Y, Chan E, Rintoul L, Islam N, et al. Excipient interactions in glucagon dry powder inhaler formulation for pulmonary delivery. Pharmaceutics (2019) 11:207. 10.3390/pharmaceutics11050207</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11050207</ArticleId><ArticleId IdType="pmc">PMC6571834</ArticleId><ArticleId IdType="pubmed">31052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan V, Naske CD, Britten CN, Karimi L, Walters KB. Hydroxide-catalyzed cleavage of selective ester bonds in phosphatidylcholine: an FTIR study. Vibrational Spectrosc (2020) 109:103055. 10.1016/j.vibspec.2020.103055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vibspec.2020.103055</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MR, Moghal MMR, Bari FSNU, Mamun EA. Design and development of Bi-layered sustained release azithromycin tablets. Dhaka Univ J Pharm Sci (2017) 15:227–34. 10.3329/dujps.v15i2.30942</Citation><ArticleIdList><ArticleId IdType="doi">10.3329/dujps.v15i2.30942</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeli E. The use of spray freeze drying for dissolution and oral bioavailability improvement of Azithromycin. Powder Technol (2017) 319:323–31. 10.1016/j.powtec.2017.06.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.powtec.2017.06.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni G, Yadav KS, Gupta MK. QbD based approach for formulation development of spray dried microparticles of erlotinib hydrochloride for sustained release. J Drug Deliv Sci Technol (2020) 57:101684. 10.1016/j.jddst.2020.101684</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2020.101684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungaro F, d’Emmanuele di Villa Bianca R, Giovino C, Miro A, Sorrentino R, La Rotonda MI, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Controlled Release (2009) 135:25–34. 10.1016/j.jconrel.2008.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2008.12.011</ArticleId><ArticleId IdType="pubmed">19154761</ArticleId></ArticleIdList></Reference><Reference><Citation>Malamatari M, Charisi A, Malamataris S, Kachrimanis K, Nikolakakis I. Spray drying for the preparation of nanoparticle-based drug formulations as dry powders for inhalation. Processes (2020) 8:788. 10.3390/pr8070788</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pr8070788</ArticleId></ArticleIdList></Reference><Reference><Citation>Balmayor ER, Tuzlakoglu K, Azevedo HS, Reis RL. Preparation and characterization of starch-poly-ε-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applications. Acta Biomater (2009) 5:1035–45. 10.1016/j.actbio.2008.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2008.11.006</ArticleId><ArticleId IdType="pubmed">19095509</ArticleId></ArticleIdList></Reference><Reference><Citation>Party P, Kókai D, Burián K, Nagy A, Hopp B, Ambrus R, et al. Development of extra-fine particles containing nanosized meloxicam for deep pulmonary delivery: in vitro aerodynamic and cell line measurements. Eur J Pharm Sci (2022) 176:106247. 10.1016/j.ejps.2022.106247</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2022.106247</ArticleId><ArticleId IdType="pubmed">35760279</ArticleId></ArticleIdList></Reference><Reference><Citation>Chvatal A, Ambrus R, Party P, Katona G, Jójárt-Laczkovich O, Szabó-Révész P, et al. Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery. Int J Pharmaceutics (2019) 559:68–75. 10.1016/j.ijpharm.2019.01.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2019.01.034</ArticleId><ArticleId IdType="pubmed">30677482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampacci E, Marenzoni ML, Chiaradia E, Passamonti F, Ricci M, Pepe M, et al. In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for Rhodococcus equi disease treatment. Sci Rep (2018) 8:12149–11. 10.1038/s41598-018-30715-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-30715-z</ArticleId><ArticleId IdType="pmc">PMC6092326</ArticleId><ArticleId IdType="pubmed">30108265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou K, Li C, Chen D, Pan Y, Tao Y, Qu W, et al. A review on nanosystems as an effective approach against infections of Staphylococcus aureus . Int J Nanomedicine (2018) 13:7333–47. 10.2147/IJN.S169935</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S169935</ArticleId><ArticleId IdType="pmc">PMC6233487</ArticleId><ArticleId IdType="pubmed">30519018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehring A, Erdmann N, Walther J, Stiefelmaier J, Strieth D, Ulber R, et al. A simple and low-cost resazurin assay for vitality assessment across species. J Biotechnol (2021) 333:63–6. 10.1016/j.jbiotec.2021.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiotec.2021.04.010</ArticleId><ArticleId IdType="pubmed">33933484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>